ReviewEuropean journal of haematology2026
Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives.
Review in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Acalabrutinib, a second-generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off-target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site, ensures potent and sustained blockade of B cell receptor signaling, leading to disruption of key survival and proliferation pathways in malignant B cells. Long-term data from pivotal phase III trials confirmed the high efficacy of acalabrutinib-containing regimens in both treatment-naïve and relapsed/refractory CLL, showing durable progression-free survival, favorable overall survival rates, and low incidence of serious adverse events such as atrial fibrillation and hypertension, likely attributable to its improved selectivity, with limited immunosuppression and better tolerability leading to lower discontinuation rates compared to first-generation BTKi. Fixed-duration combination with acalabrutinib plus venetoclax, with or without obinutuzumab, has recently emerged as a highly efficacious strategy, providing sustained minimal residual disease (MRD) negativity with manageable toxicity, further supporting the clinical utility of acalabrutinib regimens. The demonstrated efficacy, robust safety, and flexibility of acalabrutinib in both continuous and fixed-duration regimens make it a cornerstone for individualized CLL management, enabling tailored treatment approaches based on patient- and disease-specific factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.